404 related articles for article (PubMed ID: 22921719)
1. Intravesical bacille Calmette-Guérin eradicates bacteriuria in antibiotic-naïve bladder cancer patients.
Herr HW
Eur Urol; 2013 May; 63(5):832-5. PubMed ID: 22921719
[TBL] [Abstract][Full Text] [Related]
2. Outpatient urological procedures in antibiotic-naive patients with bladder cancer with asymptomatic bacteriuria.
Herr HW
BJU Int; 2012 Dec; 110(11 Pt B):E658-60. PubMed ID: 22883017
[TBL] [Abstract][Full Text] [Related]
3. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
Martínez-Piñeiro L; Portillo JA; Fernández JM; Zabala JA; Cadierno I; Moyano JL; Solsona E; Unda M; Beardo P; Rodríguez-Molina J; Chantada V; Palou J; Muntañola P; Alonso Dorrego JM; Pérez-Garcia FJ; Silva JM; Chesa N; Montesinos M; Ojea A; Madero R; Martínez-Piñeiro JA
Eur Urol; 2015 Aug; 68(2):256-62. PubMed ID: 25794457
[TBL] [Abstract][Full Text] [Related]
4. Intravesical bacillus Calmette-Guérin outcomes in patients with bladder cancer and asymptomatic bacteriuria.
Herr HW
J Urol; 2012 Feb; 187(2):435-7. PubMed ID: 22177154
[TBL] [Abstract][Full Text] [Related]
5. Intravesical bacille Calmette-Guérin (BCG) in immunologically compromised patients with bladder cancer.
Herr HW; Dalbagni G
BJU Int; 2013 May; 111(6):984-7. PubMed ID: 23351086
[TBL] [Abstract][Full Text] [Related]
6. Screening urine analysis before bacille Calmette-Guérin instillation does not reduce the rate of infectious complications.
Zhao LC; Meeks JJ; Helfand BT; Ross FR; Herr HW; Kundu SD
BJU Int; 2012 Jun; 109(12):1819-21. PubMed ID: 22077819
[TBL] [Abstract][Full Text] [Related]
7. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy.
Barlow L; McKiernan J; Sawczuk I; Benson M
BJU Int; 2009 Oct; 104(8):1098-102. PubMed ID: 19389012
[TBL] [Abstract][Full Text] [Related]
8. Should antibiotics be given prior to outpatient cystoscopy? A plea to urologists to practice antibiotic stewardship.
Herr HW
Eur Urol; 2014 Apr; 65(4):839-42. PubMed ID: 24012206
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Intravesical Bacillus Calmette-Guérin Immunotherapy in Patients with Non-Muscle-Invasive Bladder Cancer Presenting with Asymptomatic Bacteriuria: A Systematic Review.
Poletajew S; Zapała P; Radziszewski P
Urol Int; 2017; 99(1):1-5. PubMed ID: 28601885
[TBL] [Abstract][Full Text] [Related]
10. A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer.
Chen CH; Yang HJ; Shun CT; Huang CY; Huang KH; Yu HJ; Pu YS
Urol Oncol; 2012; 30(4):421-7. PubMed ID: 20870427
[TBL] [Abstract][Full Text] [Related]
11. Bacillus Calmette-Guérin without maintenance therapy for high-risk non-muscle-invasive bladder cancer.
Herr HW; Dalbagni G; Donat SM
Eur Urol; 2011 Jul; 60(1):32-6. PubMed ID: 21497431
[TBL] [Abstract][Full Text] [Related]
12. Effect of intravesical instillation on performance of uCYT+ test.
Lodde M; Mian C; Negri G; Vittadello F; Comploj E; Palermo S; Staffler A; Brössner C; Pycha A
Urology; 2004 May; 63(5):878-81. PubMed ID: 15134970
[TBL] [Abstract][Full Text] [Related]
13. Should follow-up cystoscopy in bacillus Calmette-Guérin-treated patients continue after five tumour-free years?
Holmäng S; Ströck V
Eur Urol; 2012 Mar; 61(3):503-7. PubMed ID: 22119022
[TBL] [Abstract][Full Text] [Related]
14. Does asymptomatic bacteriuria affect the response to intravesical bacillus Calmette-Guérin?
Herr H
Int J Urol; 2020 Jan; 27(1):72-74. PubMed ID: 31661717
[TBL] [Abstract][Full Text] [Related]
15. Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence.
Ehdaie B; Sylvester R; Herr HW
Eur Urol; 2013 Oct; 64(4):579-85. PubMed ID: 23711538
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment.
Kakiashvili DM; van Rhijn BW; Trottier G; Jewett MA; Fleshner NE; Finelli A; Azuero J; Bangma CH; Vajpeyi R; Alkhateeb S; Hanna S; Kostynsky A; Kuk C; Van Der Kwast TH; Zlotta AR
BJU Int; 2011 Feb; 107(4):540-6. PubMed ID: 21276177
[TBL] [Abstract][Full Text] [Related]
17. Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guérin.
Ray ER; Chatterton K; Khan MS; Chandra A; Thomas K; Dasgupta P; O'Brien TS
BJU Int; 2010 Mar; 105(6):789-94. PubMed ID: 19832725
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR.
Orsola A; Cecchini L; Raventós CX; Trilla E; Planas J; Landolfi S; de Torres I; Morote J
BJU Int; 2010 Jan; 105(2):202-7. PubMed ID: 19558557
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
[TBL] [Abstract][Full Text] [Related]
20. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
Yutkin V; Pode D; Pikarsky E; Mandelboim O
J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
